ERBB2 and breast carcinoma: Zheng et al. reported recently that tumors with a HER2/CEP17 ratio of > 7, termed “ultra-positive,” demonstrated inferior DFS than the normal-positive group among non-metastatic HER2-positive breast cancer patients receiving trastuzumab alone [45].